NIH Launches First U.S. Research Consortium Focused on SJS/TEN and Other Severe Drug Reactions

NIH Launches First U.S. Research Consortium Focused on SJS/TEN and Other Severe Drug Reactions

A major new U.S. SJS/TEN research effort

The National Institutes of Health is funding a new national Severe Cutaneous Adverse Reaction (SCAR) Clinical Research Consortium led by Vanderbilt University Medical Center. Announced October 5, 2026, the award is expected to total approximately $8.5 million over five years. Vanderbilt describes it as the first U.S. consortium devoted specifically to rare, life-threatening immune reactions to medications that can cause skin blistering and detachment, organ injury, blindness, and death.

For people affected by Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), the most important aspect of the announcement is not the funding figure. It is the consortium's plan to build a large, carefully confirmed U.S. SJS/TEN cohort and biorepository and to improve the scientific tools used to identify culprit drugs, measure disease severity, and understand long-term outcomes.

What the consortium plans to study

The consortium is part of the NIH Rare Diseases Clinical Research Network and includes 13 centers and 23 investigators across dermatology, allergy and immunology, infectious diseases, pediatrics, rheumatology, ophthalmology, clinical pharmacology, and informatics. NIH support comes through the National Institute of Allergy and Infectious Diseases, the National Center for Advancing Translational Sciences, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases.

One project, SJS-ENCORE, will be led by Benjamin Kaffenberger, MD, at The Ohio State University. Vanderbilt says the project will create the largest carefully confirmed long-term cohort and biorepository of SJS/TEN patients in the United States and validate tools for measuring disease severity and outcomes.

Another part of the consortium will develop an integrated approach using genetic testing, skin testing, and laboratory assays to improve identification of the medication responsible for a severe cutaneous adverse reaction. The network also includes work on severe reactions associated with immune checkpoint inhibitors, an increasingly important area as cancer immunotherapies are used more widely.

Why culprit-drug identification matters in an SJS/TEN case

Determining which medication caused SJS or TEN is often one of the hardest parts of both medical care and legal case evaluation. Many patients are taking several medications when symptoms begin. Some drugs may have been started recently, others may have been taken for months or years, and infections or other clinical factors can complicate the analysis.

Legal evaluation therefore requires more than identifying every drug listed in the hospital chart. The medication timeline, latency from first dose to symptoms, prior exposure, dechallenge information, known drug-specific associations, alternative causes, and the patient's clinical course all matter. Tools such as ALDEN can assist structured culprit-drug assessment, but difficult cases can remain uncertain.

If the new consortium ultimately validates better genetic, skin, or laboratory methods for culprit identification, that could become important to future SJS/TEN causation analysis. At present, however, the consortium's announcement does not establish a new diagnostic test or change the evidentiary standard for proving that a particular medication caused an individual patient's SJS/TEN.

Why this matters for pharmaceutical liability

Better causation science can have consequences beyond diagnosis. A viable pharmaceutical case generally requires identification of the actual drug product and a legally viable defendant. That means pharmacy dispensing records, National Drug Codes, manufacturer identity, brand-versus-generic exposure, prescribing records, and the label in effect at the time of treatment remain essential.

A scientifically persuasive conclusion that a drug caused SJS/TEN does not automatically establish product liability. Warning adequacy, warning chronology, federal preemption, the learned-intermediary doctrine, applicable state law, and statutes of limitation can independently determine whether a claim is viable. Generic-drug exposure can be especially important because federal preemption can sharply restrict conventional failure-to-warn claims against generic manufacturers.

For California cases, the same distinction remains critical: stronger medical causation evidence may improve factual evaluation, but it does not eliminate the need to analyze the manufacturer, the governing warning, available legal theories, and California limitation periods on a case-specific basis.

Long-term outcomes are another major focus

The SJS-ENCORE project is also important because SJS/TEN injury does not necessarily end when a patient leaves the hospital. Survivors may experience chronic ocular disease and vision loss, scarring, oral and genitourinary complications, pulmonary problems, pain, psychological effects, and other long-term sequelae.

A national longitudinal cohort could improve understanding of which complications persist, how they progress, and how severity should be measured. For legal cases, that type of evidence can eventually improve damages analysis and the documentation of future medical needs. It also reinforces the practical importance of preserving long-term ophthalmology, cornea, pulmonary, dermatology, gynecology or urology, rehabilitation, and mental-health records when those systems are affected.

What this announcement does - and does not - establish

This is an important research infrastructure development, not a new finding that any particular medication causes SJS/TEN. The consortium has not announced a new validated culprit-drug test, a new treatment standard, or a new pharmaceutical-liability theory. Its most consequential findings will emerge over the coming years as cohorts are assembled, biological samples are studied, and diagnostic methods are validated.

The significance now is that NIH has created a coordinated national research structure focused on questions that have long complicated SJS/TEN care and case evaluation: Why do certain patients react? Which drug was responsible? Can susceptibility be predicted? How should severity and long-term outcomes be measured? And can better evidence support clinical trials for a condition that still lacks a universally proven treatment?

What would strengthen the signal?

This development becomes more directly important to legal and client strategy if the consortium produces validated drug-specific causation tests, identifies reproducible genetic risk markers for commonly prescribed medications, publishes prospective data changing accepted latency or causation analysis, establishes new treatment or follow-up standards, or generates evidence that changes FDA labeling or prescribing recommendations.

Greg Jones Law will continue following those developments. For current SJS/TEN cases, the established fundamentals remain the same: preserve the complete medication and pharmacy history, identify the exact product and manufacturer, reconstruct the timing of exposure and symptoms, document acute and chronic injuries, and evaluate the warning and applicable law in effect when the reaction occurred.

Sources

Vanderbilt University Medical Center, "Vanderbilt Health to lead national consortium on life-threatening drug reactions of the skin," Oct. 5, 2026. https://news.vumc.org/2026/10/05/vanderbilt-health-to-lead-national-consortium-on-life-threatening-drug-reactions-of-the-skin/

NIH Rare Diseases Clinical Research Network, Severe Cutaneous Adverse Reaction (SCAR) Clinical Research Consortium, Grant U54 AI205728-01. https://www.rarediseasesnetwork.org/scar-crc

NIH RePORTER, SCAR research and meeting program information. https://reporter.nih.gov/project-details/11162761